Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study

BACKGROUND: Glioblastoma multiforme (GBM) is the most common and aggressive primary intracranial tumor. Despite modern therapies, it is still fatal with tremendously poor prognosis with a median survival of 14 months. Even though mean survival and progression-free survival (PFS) are considered as pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammed, Soniya, Dinesan, M, Ajayakumar, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826661/
https://www.ncbi.nlm.nih.gov/pubmed/36632307
http://dx.doi.org/10.5603/RPOR.a2022.0113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826661/
https://www.ncbi.nlm.nih.gov/pubmed/36632307
http://dx.doi.org/10.5603/RPOR.a2022.0113

Ejemplares similares